This epigenetic antagonism has been best characterized in SMARCB1-deficient MRT models where loss of SMARCB1 is associated with constitutive EZH2 activation and downstream oncogenic activity; in MRT preclinical models, EZH2 inhibition induced durable tumor regression and apoptosis [113,114,115]. Here, EZH2 is linked to neoplasm.